In conclusion, the results of this study showed that hypercoagulation was likely present in patients with COVID-19 at the early stage. And hypercoagulation is closely related to disease progression and clinical outcome. Therefore, the coagulation indicators such as DD and PT should be monitored as early as possible in order to detect thrombotic complications. It is imperative to take preventive treatment to reduce the risk of thromboembolism and DIC secondary to coagulation disorder, thereby decreasing the morbidity and mortality of COVID-19-infected patients.